News and Trends 15 Nov 2022
First patient dosed in Nouscom colorectal cancer study
Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, says the first patient has been dosed in a randomized phase 2 clinical trial evaluating NOUS-209 in combination with…